Stock Buzzer: ICON PLC Declines Again; Strong Momentum for Sellers

Stock Buzzer: ICON PLC Declines Again; Strong Momentum for Sellers

The stock of ICON PLC (NASDAQ:ICLR) is a huge mover today! About 663,291 shares traded hands or 22.26% up from the average. ICON PLC (NASDAQ:ICLR) has risen 8.64% since April 14, 2016 and is uptrending. It has outperformed by 3.95% the S&P500.
The move comes after 7 months negative chart setup for the $4.23B company. It was reported on Nov, 16 by Barchart.com. We have $70.68 PT which if reached, will make NASDAQ:ICLR worth $380.70M less.

ICON PLC (NASDAQ:ICLR) Ratings Coverage

Out of 6 analysts covering Icon plc (NASDAQ:ICLR), 4 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 67% are positive. Icon plc has been the topic of 9 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The stock of ICON PLC (NASDAQ:ICLR) earned “Mkt Underperform” rating by Avondale on Thursday, June 9. Credit Suisse initiated ICON PLC (NASDAQ:ICLR) rating on Tuesday, June 21. Credit Suisse has “Outperform” rating and $80 price target. The rating was reinitiated by Credit Suisse on Friday, August 14 with “Outperform”. The company was upgraded on Friday, October 14 by Evercore. The company was maintained on Wednesday, July 27 by Jefferies. The firm has “Market Perform” rating by Avondale given on Wednesday, October 21. The firm earned “Hold” rating on Friday, June 3 by Jefferies.

According to Zacks Investment Research, “ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide.”

More notable recent ICON PLC (NASDAQ:ICLR) news were published by: Streetinsider.com which released: “ICON plc (ICLR) to Acquire ClinicalRM” on June 30, 2016, also Streetinsider.com with their article: “ICON plc (ICLR) Tops Q3 EPS by 1c” published on October 20, 2016, Seekingalpha.com published: “ICON Plc (ICLR) Ciaran Murray on Q2 2016 Results – Earnings Call Transcript” on July 26, 2016. More interesting news about ICON PLC (NASDAQ:ICLR) were released by: Streetinsider.com and their article: “ICON plc (ICLR) Announces Completion of Clinical Research Management Acquisition” published on September 19, 2016 as well as Streetinsider.com‘s news article titled: “ICON plc (ICLR) Appoints New CEO, Chairman” with publication date: October 20, 2016.

ICLR Company Profile

ICON public limited company, incorporated on May 31, 1989, is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Firm is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies. The Company’s services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. The Company’s areas of operation outside of Ireland include the United States, the United Kingdom, France, Germany, Italy, Spain, The Netherlands, Sweden, Turkey, Poland, Czech Republic, Latvia, Russia, Ukraine, Hungary, Israel, Romania, Switzerland, Canada, Mexico, Brazil, Colombia, Argentina, Chile, Peru, India, China, South Korea, Japan, Thailand, Taiwan, Singapore, The Philippines, Australia, New Zealand and South Africa.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment